OS-01: The Senolytic Peptide With Actual Human RCT Data
In a field drowning in mouse data and theoretical mechanisms, OS-01 (also known as Peptide 14) stands out for a simple reason: it has published human RCT data. Not a case report. Not an observational cohort. A randomized, controlled, double-blind trial in human subjects.
What OS-01 Is
OS-01 is a proprietary peptide developed by OneSkin Technologies designed to function as a senotherapeutic -- a compound that modulates the behavior of senescent cells. While pure senolytics (like FOXO4-DRI) kill senescent cells outright, senotherapeutics may also suppress the SASP, reduce senescent-cell burden through other mechanisms, or shift the senescent phenotype toward a less inflammatory state.
OS-01 was identified through a screening program that tested peptide libraries against human skin cell models of senescence, selecting for compounds that reduced senescence markers without cytotoxicity.
The Human RCT
The published clinical trial evaluated OS-01 as a topical formulation applied to human skin. Key design elements:
- Randomized, double-blind, placebo-controlled design
- Measured skin-barrier function, senescence markers (p16, p21, SA-beta-gal), and epigenetic age (skin-specific DNA methylation clocks)
- Results showed improved barrier function and reduced molecular markers of skin aging
The significance isn’t that OS-01 revolutionized dermatology. It’s that a longevity peptide was tested in the gold-standard trial format and produced measurable results. In a field where most “anti-aging” peptide claims rest on in-vitro data or animal models, this is a meaningful evidence threshold.
The Topical Limitation
OS-01’s data is topical skin application only. It does not address systemic senescent-cell clearance. Skin is the most accessible tissue for senolytic intervention, and the results cannot be extrapolated to organs like the brain, kidneys, or vasculature.
For systemic senolytic effects, researchers continue to investigate small molecules (dasatinib + quercetin, navitoclax) and peptides (FOXO4-DRI) that can be delivered systemically. OS-01’s contribution is proof-of-principle that peptide-based senotherapeutics can produce measurable human outcomes in a controlled setting.
Commercial Context
OneSkin sells OS-01-containing topical products directly to consumers. This is a cosmeceutical/skincare product, not a pharmaceutical. No FDA approval is required for topical skincare products, and none has been sought. The clinical trial was conducted to support marketing claims and publish peer-reviewed evidence.
BioPure Peptides
Research-grade peptides with third-party purity testing and certificates of analysis.
Shop BioPure Peptides →POWER at checkoutFrequently Asked Questions
OS-01 (Peptide 14) is a senotherapeutic peptide developed by OneSkin that targets senescent cells in skin tissue. It has published human RCT data showing improved skin-barrier function and reduced molecular aging markers.
No. OS-01 is sold as a topical skincare product, which does not require FDA approval. The clinical trial was conducted to generate peer-reviewed evidence supporting its mechanism, not for regulatory approval.
FOXO4-DRI is a systemic senolytic that kills senescent cells through p53 release. OS-01 is a topical senotherapeutic that modulates senescence in skin. They target the same biological problem through different mechanisms and delivery routes.
No. OS-01 data is limited to topical skin application. Systemic senescent-cell clearance requires systemically delivered compounds. OS-01 provides proof-of-principle for peptide senotherapeutics but is not a whole-body anti-aging intervention.
Related Articles
Not Sure Which Peptide Is Right for You?
Take our free 60-second quiz and get personalized recommendations based on your goals.
Take the Quiz →